The Changing Dynamics of Cancer Drug Development

The growing number and size of oncology players has made the field far more competitive, eroding--or at least, shifting--some of the advantages that continue to attract smaller firms to the field.

Oncology is probably the most popular therapeutic area for drug development. About a third of all drug candidates in development are for oncology indications. There are over 150 candidates in Phase III trials, including both new compounds and marketed products being developed for new indications.

The rationale is simple. The medical need is high. Compared to primary care drugs, oncology medicines look cheap to develop...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo